Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 204

1.

Microvascular blood flow during vascular occlusion tests assessed by diffuse correlation spectroscopy.

Didier KD, Hammer SM, Alexander AM, Caldwell JT, Sutterfield SL, Smith JR, Ade CJ, Barstow TJ.

Exp Physiol. 2020 Jan;105(1):201-210. doi: 10.1113/EP087866. Epub 2019 Dec 20.

PMID:
31713942
2.

Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk.

Neidich SD, Fong Y, Li SS, Geraghty DE, Williamson BD, Young WC, Goodman D, Seaton KE, Shen X, Sawant S, Zhang L, deCamp AC, Blette BS, Shao M, Yates NL, Feely F, Pyo CW, Ferrari G; HVTN 505 Team, Frank I, Karuna ST, Swann EM, Mascola JR, Graham BS, Hammer SM, Sobieszczyk ME, Corey L, Janes HE, McElrath MJ, Gottardo R, Gilbert PB, Tomaras GD.

J Clin Invest. 2019 Nov 1;129(11):4838-4849. doi: 10.1172/JCI126391.

3.

Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial.

Li SS, Gilbert PB, Carpp LN, Pyo CW, Janes H, Fong Y, Shen X, Neidich SD, Goodman D, deCamp A, Cohen KW, Ferrari G, Hammer SM, Sobieszczyk ME, Mulligan MJ, Buchbinder SP, Keefer MC, DeJesus E, Novak RM, Frank I, McElrath MJ, Tomaras GD, Geraghty DE, Peng X.

J Virol. 2019 Oct 15;93(21). pii: e02041-18. doi: 10.1128/JVI.02041-18. Print 2019 Nov 1.

PMID:
31434737
4.

Prediction of Emergency Capsule Egress Performance.

Alexander AM, Sutterfield SL, Kriss KN, Hammer SM, Didier KD, Cauldwell JT, Dzewaltowski AC, Barstow TJ, Ade CJ.

Aerosp Med Hum Perform. 2019 Sep 1;90(9):782-787. doi: 10.3357/AMHP.5307.2019.

PMID:
31426893
5.

Effect of assuming constant tissue scattering on measured tissue oxygenation values during tissue ischemia and vascular reperfusion.

Hammer SM, Hueber DM, Townsend DK, Huckaby LM, Alexander AM, Didier KD, Barstow TJ.

J Appl Physiol (1985). 2019 Apr 18. doi: 10.1152/japplphysiol.01138.2018. [Epub ahead of print]

PMID:
30998126
6.

Prediction of Planetary Mission Task Performance for Long-Duration Spaceflight.

Sutterfield SL, Alexander AM, Hammer SM, Didier KD, Caldwell JT, Barstow TJ, Ade CJ.

Med Sci Sports Exerc. 2019 Aug;51(8):1662-1670. doi: 10.1249/MSS.0000000000001980.

PMID:
30882564
7.

Exercise tolerance through severe and extreme intensity domains.

Alexander AM, Didier KD, Hammer SM, Dzewaltowski AC, Kriss KN, Lovoy GM, Hammer JL, Smith JR, Ade CJ, Broxterman RM, Barstow TJ.

Physiol Rep. 2019 Mar;7(5):e14014. doi: 10.14814/phy2.14014.

8.

Vasoconstrictor responsiveness through alterations in relaxation time and metabolic rate during rhythmic handgrip contractions.

Caldwell JT, Sutterfield SL, Post HK, Lovoy GM, Banister HR, Hammer SM, Ade CJ.

Physiol Rep. 2018 Dec;6(23):e13933. doi: 10.14814/phy2.13933.

9.

The noninvasive simultaneous measurement of tissue oxygenation and microvascular hemodynamics during incremental handgrip exercise.

Hammer SM, Alexander AM, Didier KD, Smith JR, Caldwell JT, Sutterfield SL, Ade CJ, Barstow TJ.

J Appl Physiol (1985). 2018 Mar 1;124(3):604-614. doi: 10.1152/japplphysiol.00815.2017. Epub 2017 Dec 14.

10.

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial.

Fong Y, Shen X, Ashley VC, Deal A, Seaton KE, Yu C, Grant SP, Ferrari G, deCamp AC, Bailer RT, Koup RA, Montefiori D, Haynes BF, Sarzotti-Kelsoe M, Graham BS, Carpp LN, Hammer SM, Sobieszczyk M, Karuna S, Swann E, DeJesus E, Mulligan M, Frank I, Buchbinder S, Novak RM, McElrath MJ, Kalams S, Keefer M, Frahm NA, Janes HE, Gilbert PB, Tomaras GD.

J Infect Dis. 2018 Mar 28;217(8):1280-1288. doi: 10.1093/infdis/jiy008.

11.

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.

deCamp AC, Rolland M, Edlefsen PT, Sanders-Buell E, Hall B, Magaret CA, Fiore-Gartland AJ, Juraska M, Carpp LN, Karuna ST, Bose M, LePore S, Miller S, O'Sullivan A, Poltavee K, Bai H, Dommaraju K, Zhao H, Wong K, Chen L, Ahmed H, Goodman D, Tay MZ, Gottardo R, Koup RA, Bailer R, Mascola JR, Graham BS, Roederer M, O'Connell RJ, Michael NL, Robb ML, Adams E, D'Souza P, Kublin J, Corey L, Geraghty DE, Frahm N, Tomaras GD, McElrath MJ, Frenkel L, Styrchak S, Tovanabutra S, Sobieszczyk ME, Hammer SM, Kim JH, Mullins JI, Gilbert PB.

PLoS One. 2017 Nov 17;12(11):e0185959. doi: 10.1371/journal.pone.0185959. eCollection 2017.

12.

Left ventricular strain rate is reduced during voluntary apnea in healthy humans.

Smith JR, Sutterfield SL, Baumfalk DR, Didier KD, Hammer SM, Caldwell JT, Ade CJ.

J Appl Physiol (1985). 2017 Dec 1;123(6):1730-1737. doi: 10.1152/japplphysiol.00327.2017. Epub 2017 Sep 14.

13.

Effect of cyclooxygenase inhibition on the inspiratory muscle metaboreflex-induced cardiovascular consequences in men.

Smith JR, Didier KD, Hammer SM, Alexander AM, Kurti SP, Copp SW, Barstow TJ, Harms CA.

J Appl Physiol (1985). 2017 Jul 1;123(1):197-204. doi: 10.1152/japplphysiol.00165.2017. Epub 2017 May 18.

14.

Cardiovascular consequences of the inspiratory muscle metaboreflex: effects of age and sex.

Smith JR, Alexander AM, Hammer SM, Didier KD, Kurti SP, Broxterman RM, Barstow TJ, Harms CA.

Am J Physiol Heart Circ Physiol. 2017 May 1;312(5):H1013-H1020. doi: 10.1152/ajpheart.00818.2016. Epub 2017 Feb 24.

15.

Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.

Janes HE, Cohen KW, Frahm N, De Rosa SC, Sanchez B, Hural J, Magaret CA, Karuna S, Bentley C, Gottardo R, Finak G, Grove D, Shen M, Graham BS, Koup RA, Mulligan MJ, Koblin B, Buchbinder SP, Keefer MC, Adams E, Anude C, Corey L, Sobieszczyk M, Hammer SM, Gilbert PB, McElrath MJ.

J Infect Dis. 2017 May 1;215(9):1376-1385. doi: 10.1093/infdis/jix086.

16.

Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence.

Hanscom B, Janes HE, Guarino PD, Huang Y, Brown ER, Chen YQ, Hammer SM, Gilbert PB, Donnell DJ.

J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):606-608.

17.

Sex differences in the cardiovascular consequences of the inspiratory muscle metaboreflex.

Smith JR, Broxterman RM, Hammer SM, Alexander AM, Didier KD, Kurti SP, Barstow TJ, Harms CA.

Am J Physiol Regul Integr Comp Physiol. 2016 Sep 1;311(3):R574-81. doi: 10.1152/ajpregu.00187.2016. Epub 2016 Aug 3.

18.

Acute supplementation of N-acetylcysteine does not affect muscle blood flow and oxygenation characteristics during handgrip exercise.

Smith JR, Broxterman RM, Ade CJ, Evans KK, Kurti SP, Hammer SM, Barstow TJ, Harms CA.

Physiol Rep. 2016 Apr;4(7). pii: e12748. doi: 10.14814/phy2.12748.

19.

Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.

Walsh SR, Moodie Z, Fiore-Gartland AJ, Morgan C, Wilck MB, Hammer SM, Buchbinder SP, Kalams SA, Goepfert PA, Mulligan MJ, Keefer MC, Baden LR, Swann EM, Grant S, Ahmed H, Li F, Hertz T, Self SG, Friedrich D, Frahm N, Liao HX, Montefiori DC, Tomaras GD, McElrath MJ, Hural J, Graham BS, Jin X; HVTN 083 Study Group and the NIAID HVTN.

J Infect Dis. 2016 Feb 15;213(4):541-50. doi: 10.1093/infdis/jiv496. Epub 2015 Oct 15.

20.

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.

Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC, Churchyard G, Robb ML, Fast PE, Duerr A, McElrath MJ, Corey L, Mascola JR, Graham BS, Sobieszczyk ME, Kublin JG, Robertson M, Hammer SM, Gray GE, Buchbinder SP, Gilbert PB.

PLoS One. 2015 Sep 2;10(9):e0136626. doi: 10.1371/journal.pone.0136626. eCollection 2015.

21.

Testing the waters: Ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial.

Dawson L, Garner S, Anude C, Ndebele P, Karuna S, Holt R, Broder G, Handibode J, Hammer SM, Sobieszczyk ME; NIAID HIV Vaccine Trials Network.

Clin Trials. 2015 Aug;12(4):394-402. doi: 10.1177/1740774515579165. Epub 2015 Apr 7.

22.

Ebola and quarantine.

Drazen JM, Kanapathipillai R, Campion EW, Rubin EJ, Hammer SM, Morrissey S, Baden LR.

N Engl J Med. 2014 Nov 20;371(21):2029-30. doi: 10.1056/NEJMe1413139. Epub 2014 Oct 27. No abstract available.

23.

Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants.

Frey SE, Peiperl L, McElrath MJ, Kalams S, Goepfert PA, Keefer MC, Baden LR, Lally MA, Mayer K, Blattner WA, Harro CD, Hammer SM, Gorse GJ, Hural J, Tomaras GD, Levy Y, Gilbert P, deCamp A, Russell ND, Elizaga M, Allen M, Corey L.

Clin Vaccine Immunol. 2014 Nov;21(11):1589-99. doi: 10.1128/CVI.00450-14. Epub 2014 Sep 24.

24.

Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial.

Safren SA, Biello KB, Smeaton L, Mimiaga MJ, Walawander A, Lama JR, Rana A, Nyirenda M, Kayoyo VM, Samaneka W, Joglekar A, Celentano D, Martinez A, Remmert JE, Nair A, Lalloo UG, Kumarasamy N, Hakim J, Campbell TB; PEARLS (ACTG A5175) Study Team.

PLoS One. 2014 Aug 25;9(8):e104178. doi: 10.1371/journal.pone.0104178. eCollection 2014.

25.

Patterns of geographic mobility predict barriers to engagement in HIV care and antiretroviral treatment adherence.

Taylor BS, Reyes E, Levine EA, Khan SZ, Garduño LS, Donastorg Y, Hammer SM, Brudney K, Hirsch JS.

AIDS Patient Care STDS. 2014 Jun;28(6):284-95. doi: 10.1089/apc.2014.0028. Epub 2014 May 19.

26.

Cancer-related impairments influence physical activity in uterine cancer survivors.

Hammer SM, Brown JC, Segal S, Chu CS, Schmitz KH.

Med Sci Sports Exerc. 2014 Dec;46(12):2195-201. doi: 10.1249/MSS.0000000000000360.

27.

Structure determination from powder data without prior indexing, using a similarity measure based on cross-correlation functions.

Habermehl S, Mörschel P, Eisenbrandt P, Hammer SM, Schmidt MU.

Acta Crystallogr B Struct Sci Cryst Eng Mater. 2014 Apr;70(Pt 2):347-59. doi: 10.1107/S2052520613033994. Epub 2014 Mar 28.

PMID:
24675604
28.

Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.

Boltz VF, Bao Y, Lockman S, Halvas EK, Kearney MF, McIntyre JA, Schooley RT, Hughes MD, Coffin JM, Mellors JW; OCTANE/A5208 Team.

J Infect Dis. 2014 Mar 1;209(5):703-10. doi: 10.1093/infdis/jit635. Epub 2014 Jan 16.

29.

Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Goepfert PA, Elizaga ML, Seaton K, Tomaras GD, Montefiori DC, Sato A, Hural J, DeRosa SC, Kalams SA, McElrath MJ, Keefer MC, Baden LR, Lama JR, Sanchez J, Mulligan MJ, Buchbinder SP, Hammer SM, Koblin BA, Pensiero M, Butler C, Moss B, Robinson HL; HVTN 205 Study Group; National Institutes of Allergy and Infectious Diseases HIV Vaccines Trials Network.

J Infect Dis. 2014 Jul 1;210(1):99-110. doi: 10.1093/infdis/jiu003. Epub 2014 Jan 7.

30.

Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.

Smith KY, Tierney C, Mollan K, Venuto CS, Budhathoki C, Ma Q, Morse GD, Sax P, Katzenstein D, Godfrey C, Fischl M, Daar ES, Collier AC; AIDS Clinical Trials Group 5202 Study Team.

Clin Infect Dis. 2014 Feb;58(4):555-63. doi: 10.1093/cid/cit747. Epub 2013 Nov 18.

31.

Baby steps on the road to HIV eradication.

Hammer SM.

N Engl J Med. 2013 Nov 7;369(19):1855-7. doi: 10.1056/NEJMe1309006. Epub 2013 Oct 23. No abstract available.

PMID:
24152231
32.

207-nm UV light - a promising tool for safe low-cost reduction of surgical site infections. I: in vitro studies.

Buonanno M, Randers-Pehrson G, Bigelow AW, Trivedi S, Lowy FD, Spotnitz HM, Hammer SM, Brenner DJ.

PLoS One. 2013 Oct 16;8(10):e76968. doi: 10.1371/journal.pone.0076968. eCollection 2013.

33.

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, Adams E, DeJesus E, Novak RM, Frank I, Bentley C, Ramirez S, Fu R, Koup RA, Mascola JR, Nabel GJ, Montefiori DC, Kublin J, McElrath MJ, Corey L, Gilbert PB; HVTN 505 Study Team.

N Engl J Med. 2013 Nov 28;369(22):2083-92. doi: 10.1056/NEJMoa1310566. Epub 2013 Oct 7.

34.

A two-dimensional polymer from the anthracene dimer and triptycene motifs.

Bhola R, Payamyar P, Murray DJ, Kumar B, Teator AJ, Schmidt MU, Hammer SM, Saha A, Sakamoto J, Schlüter AD, King BT.

J Am Chem Soc. 2013 Sep 25;135(38):14134-41. doi: 10.1021/ja404351p. Epub 2013 Sep 17.

PMID:
24044739
35.

Translational research insights from completed HIV vaccine efficacy trials.

Tieu HV, Rolland M, Hammer SM, Sobieszczyk ME.

J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S150-4. doi: 10.1097/QAI.0b013e31829a3985. Review.

PMID:
23764628
36.

CROI 2013: Advances in antiretroviral therapy.

Taylor BS, Wilkin TJ, Shalev N, Hammer SM.

Top Antivir Med. 2013 Apr-May;21(2):75-89. Review.

37.

Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of Treatment.

Zhang X, Hunt PW, Hammer SM, Cespedes MS, Patterson KB, Bosch RJ.

HIV Clin Trials. 2013 Mar-Apr;14(2):61-7. doi: 10.1310/hct1402-61.

38.

In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalities.

Janes H, Gilbert P, Buchbinder S, Kublin J, Sobieszczyk ME, Hammer SM.

AIDS Res Hum Retroviruses. 2013 Nov;29(11):1513-23. doi: 10.1089/AID.2012.0385. Epub 2013 Jun 25.

39.

Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy.

Fiscus SA, Cu-Uvin S, Eshete AT, Hughes MD, Bao Y, Hosseinipour M, Grinsztejn B, Badal-Faesen S, Dragavon J, Coombs RW, Braun K, Moran L, Hakim J, Flanigan T, Kumarasamy N, Campbell TB; A5185s Team.

Clin Infect Dis. 2013 Jul;57(2):290-7. doi: 10.1093/cid/cit195. Epub 2013 Mar 26.

40.

A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens.

Gilbert PB, Grove D, Gabriel E, Huang Y, Gray G, Hammer SM, Buchbinder SP, Kublin J, Corey L, Self SG.

Stat Commun Infect Dis. 2011 Oct;3(1). pii: 1037.

41.

Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings.

Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C, Grinsztejn B, Hosseinipour MC, Kumwenda J, Lalloo U, Riviere C, Sanchez J, Melo M, Supparatpinyo K, Tripathy S, Martinez AI, Nair A, Walawander A, Moran L, Chen Y, Snowden W, Rooney JF, Uy J, Schooley RT, De Gruttola V, Hakim JG; PEARLS study team of the ACTG.

PLoS Med. 2012;9(8):e1001290. Epub 2012 Aug 14.

42.

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Günthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA.

JAMA. 2012 Jul 25;308(4):387-402. doi: 10.1001/jama.2012.7961.

PMID:
22820792
43.

Advances in antiretroviral therapy.

Olender S, Wilkin TJ, Taylor BS, Hammer SM.

Top Antivir Med. 2012 Jun-Jul;20(2):61-86. Review.

44.

Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study).

Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Gilbert P, Corey L, Robertson MN; Step/HVTN 504 Study Team.

J Infect Dis. 2012 Jul 15;206(2):258-66. doi: 10.1093/infdis/jis342. Epub 2012 May 4.

45.

Crystal structures of the hydration states of Pigment Red 57:1.

Bekö SL, Hammer SM, Schmidt MU.

Angew Chem Int Ed Engl. 2012 May 7;51(19):4735-8. doi: 10.1002/anie.201109082. Epub 2012 Mar 29. No abstract available.

PMID:
22461339
46.

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.

Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Feinberg J, Tashima K, Murphy RL, Fischl MA; AIDS Clinical Trials Group Study A5202 Team.

J Infect Dis. 2011 Oct 15;204(8):1191-201. doi: 10.1093/infdis/jir505.

47.

Advances in antiretroviral therapy.

Taylor B, Olender S, Wilkin TJ, Hammer SM.

Top Antivir Med. 2011 May-Jun;19(2):69-97. Review.

48.

Transmitted drug resistance among antiretroviral-naive patients with established HIV type 1 infection in Santo Domingo, Dominican Republic and review of the Latin American and Caribbean literature.

Myers JE, Taylor BS, Rojas Fermín RA, Reyes EV, Vaughan C, José L, Javier C, Franco Estévez R, Donastorg Cabral Y, Batista A, Lie Y, Coakley E, Hammer SM, Brudney K.

AIDS Res Hum Retroviruses. 2012 Jul;28(7):667-74. doi: 10.1089/AID.2010.0355. Epub 2011 Sep 23. Review.

49.

Antiretroviral treatment as prevention.

Hammer SM.

N Engl J Med. 2011 Aug 11;365(6):561-2. doi: 10.1056/NEJMe1107487. Epub 2011 Jul 18. No abstract available.

PMID:
21767102
50.

Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans.

Pine SO, Kublin JG, Hammer SM, Borgerding J, Huang Y, Casimiro DR, McElrath MJ.

PLoS One. 2011 Apr 13;6(4):e18526. doi: 10.1371/journal.pone.0018526.

Supplemental Content

Loading ...
Support Center